Indications for Hematopoietic Cell Transplantation in Acute Leukemia

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 1 SUPPL., 2008, Pages 154-164

  Davies, Stella M ^a   Rowe, Jacob M ^b   Appelbaum, Frederick R ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IMATINIB; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MORTALITY; MULTIPLE CYCLE TREATMENT; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; RECURRENT CANCER; REDUCED INTENSITY CONDITIONING; TREATMENT INDICATION; WHOLE BODY RADIATION;

ADULT; AGE FACTORS; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; PATIENT SELECTION;

EID: 37349013279     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.10.024     Document Type: Article

References (69)

1. Schultz K.R., Pullen D.J., Sather H.N., et al. Risk-and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 109 (2007) 926-935
2. Ravindranath Y., Chang M., Steuber C.P., et al. Pediatric Oncology Group Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19 (2005) 2101-2116
3. Castellino S.M., Alonzo T.A., Buxton A., Gold S., Lange B.J., and Woods W.G. Outcomes in childhood AML in the absence of transplantation in first remission-Children's Cancer Group (CCG) studies 2891 and CCG 213. Pediatr Blood Cancer (2007) [Epub ahead of print]
4. Ribeiro R.C., Razzouk B.I., Pounds S., Hijiya N., Pui C.H., and Rubnitz J.E. Successive clinical trials for childhood acute myeloid leukemia at St. Jude Children's Research Hospital, from 1980 to 2000. Leukemia 19 (2005) 2125-2129
5. Hongeng S., Krance R.A., Bowman L.C., et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 13 350 (1997) 767-771
6. Moore J., Nivison-Smith I., Goh K., et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 13 (2007) 601-607
7. Aricò M., Grazia Valsecchi M., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342 (2000) 998-1006
8. Marks D.I., Bird J.M., Cornish J.M., et al. Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia. J Clin Oncol 16 (1998) 931-936
9. Sierra J., Radich J., Hansen J.A., et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 90 (1997) 1410-1414
10. Roy A., Bradburn M., Moorman A., et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 129 (2005) 35-44
11. Talano J.M., Casper J.T., Camitta B.M., et al. Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. Bone Marrow Transplant 37 (2006) 135-141
12. Heerema N.A., Nachman J.B., Sather H.N., et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 94 (1999) 4036-4046
13. Nachman J.B., Heerema N.A., Sather H., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110 (2007) 1112-1115
14. Chen C.S., Sorensen H.B., Domer H., et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variable and poor outcome. Blood 81 (1993) 2386-2393
15. Pui C.-H., Gaynon P.S., Boyett J.M., et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359 (2002) 1909-1915
16. Hilden J.M., Dinndorf P.A., Meerbaum S.O., et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 108 (2006) 441-451
17. Sanders J.E., Im H.J., Hoffmeister P.A., et al. Allogeneic hemotopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 105 (2005) 3749-3756
18. Pieters R., Schrappe M., De Lorenzo P., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370 (2007) 240-250
19. Eapen M., Raetz E., Zhang M., et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 107 (2006) 4961-4967
20. Uderzo C., Valsecchi M.G., Bacigalupo A., et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 13 (1995) 352-358
21. Dopfer R., Henze G., Bender-Gotze C., et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood 78 (1991) 2780-2784
22. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
23. Hasle H., Alonzo T.A., Auvrignon A., et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 109 (2007) 4641
24. Perkins J.L., Kunin-Batson A.S., Youngren N.M., et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer (2007) [Epub ahead of print]
25. Leahey A.M., Teunissen H., Friedman D.L., Moshang T., Lange B.J., and Meadows A.T. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol 32 (1999) 163-169
26. Moorman A.V., Harrison C.J., Buck G.A., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood 109 (2007) 3189-3197
27. Rowe J.M., Buck G., Burnett A.K., et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 106 (2005) 3760-3767
28. Zhang M., Hoelzer D., Horowitz M., et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 123 (1995) 428-431
29. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300 (1979) 1068-1073
30. Thiebaut A., Vernant J.P., Degos L., et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 14 (2000) 1353-1366
31. Thomas X., Boiron J.M., Huguet F., et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22 (2004) 4075-4086
32. Hunault M., Harousseau J.L., Delain M., et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 104 (2004) 3028-3037
33. Gupta V., Yi Q.L., Brandwein J., et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant 33 (2004) 397-404
34. Rowe J.M., Buck G., Fielding A., et al. In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from an allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 108 (2006) 5a
35. Barry E., DeAngelo D.J., Neuberg D., et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 25 (2007) 813-819
36. Schiffer C.A. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?. J Clin Oncol 21 (2003) 760-761
37. Bleyer A. The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care 35 (2005) 182-217
38. Goldstone A.H., Chopra R., Buck G., et al. The outcome of 267 Philadelphia-positive adults in the International UKALL XII/ ECOG E2993 study. Final analysis and the role of allogeneic transplant in those under 50 years. [abstract]. Blood 104 (2003) 268a
39. Marks D.I., Aversa F., and Lazarus H.M. Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant 38 (2006) 467-475
40. Kiehl M.G., Kraut L., Schwerdtfeger R., et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 22 (2004) 2816-2825
41. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
42. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?. Leukemia 21 (2007) 622-626
43. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107 (2006) 1116-1123
44. Mato A.R., and Luger S.M. Autologous stem cell transplant in ALL: who should we be transplanting in first remission?. Bone Marrow Transplant 37 (2006) 989-995
45. Sebban C., Lepage E., Vernant J.P., et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 12 (1994) 2580-2587
46. Fielding A.K., Richards S.M., Chopra R., et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109 (2007) 944-950
47. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109 (2007) 1408-1413
48. Ottmann O.G. Wassmann B.Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia. Am Soc Hematol Educ Program (2005) 118-122
49. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 (2006) 460-466
50. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331 (1994) 896-903
51. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 107 (2006) 3481-3485
52. Estey E., Kornblau S., Pierce S., Kantarjian H., Beran M., and Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia (Letter). Blood 88 (1996) 756
53. Clift R.A., and Thomas E.D. Follow-up 26 years after treatment for acute myelogenous leukemia (Letter to the Editor). N Engl J Med 351 (2004) 2456-2457
54. Center for International Blood and Marrow Transplant Research. Available at: www.cibmtr.org. Accessed September 5, 2007.
55. Yanada M., Matsuo K., Emi N., and Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 103 (2005) 1652-1658
56. Schlenk R.F., Corbacioglu A., Krauter J., et al. Gene mutations as predictive markers for postremission therapy in younger adults with normal karyotype AML. Blood 108 (2006) 6a
57. Levi I., Grotto I., Yerushalmi R., Ben-Bassat I., and Shpilberg O. Meta-analysis of autologous bone marrow transplantation in adult patients with acute myeloid leukemia in first remission. Leuk Res 28 (2004) 605-612
58. Krauter J., Heil G., Hoelzer D., et al. Role of consolidation therapy in the treatment of patients up to 60years with high risk AML. Blood 106 (2006) 54a
59. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 10 (1992) 1723-1729
60. Brown R.A., Wolff S.N., Fay J.W., et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American marrow transplant group. Blood 85 (1995) 1391-1395
61. Schiffman K., Clift R., Appelbaum F.R., et al. Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia. Bone Marrow Transplant 11 (1993) 227-232
62. Lazarus H.M., Pérez W.S., and Klein J.P. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 132 (2006) 755-769
63. Estey E.H. Treatment of relapsed and refractory acute myelogenous leukemia (Review). Leukemia 14 (2000) 476-479
64. Appelbaum F.R., Clift R.A., Buckner C.D., et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood 61 (1983) 949-953
65. Sierra J., Storer B., Hansen J.A., et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 26 (2000) 397-404
66. Biggs J.C., Horowitz M.M., Gale R.P., et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 80 (1992) 1090-1093
67. Fung H.C., Stein A., Slovak M., et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 9 (2003) 766-771
68. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24 (2006) 444-453
69. Mohty M., de Lavallade H., Ladaique P., et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 19 (2005) 916-920